Keros Therapeutics shareholder ADAR1 Capital Management said it plans to withhold votes for board members Mary Ann Gray and Alpna Seth.

Beacon Therapeutics may have found a guiding light in a disease area where other companies have stumbled with its ...

Efficacy data were pooled and analyzed from three clinical trials: Phase 2 WTX101-201, Phase 2 ALXN1840-WD-205, and Phase 3 WTX101-301 (n=255). For safety analysis, data from the Phase 2 ALXN1840 ...

Top-line results from two pivotal Phase III trials found that MR-107A-02 significantly reduced pain intensity following ...

and CDK7/9 with the inhibitor BTX-A51 in human liposarcomas,” highlights new mechanistic and efficacy data in patient-derived cell lines and xenograft models. One of the most significant ...

Portage Biotech announced confirmatory preclinical efficacy data for PORT-7, demonstrating superior single agent activity compared to anti-PD1 antibody, which is a significant advancement in ...

Beacon Therapeutics reveals promising interim results for laru-zova, a gene therapy showing potential to improve vision in ...

Initial clinical safety and efficacy data are available. In addition, the study aims to identify biomarkers for the target patient population and enrichment for further trials. For more ...